MDCE 10-Q Quarterly Report Sept. 30, 2010 | Alphaminr
Medical Care Technologies Inc.
ALPHAMINR

MDCE 10-Q Quarter ended Sept. 30, 2010

Balance Sheet
Cash Flow
Income Statement
10-Q 1 f10q0910_meditech.htm FORM 10-Q f10q0910_meditech.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

x
QUARTERLY REPORT UNDER TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2010
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-53665

MEDICAL CARE TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)

NEVADA
(State or other jurisdiction of incorporation or organization)

Room 815, No. 2 Building Beixiaojie, Dongzhimen Nei
Beijing, People’s Republic of China 10009
(Address of principal executive offices, including zip code.)

(8610) 6407 0580
(Registrant’s telephone number, including area code)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files) YES o NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer, “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated Filer o Accelerated Filer o
Non-accelerated Filer o Smaller Reporting Company x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES o NO x

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: 151,226,087 as of November 19, 2010.
TABLE OF CONTENTS

Page
PART I
Item 1.  Financial Statements
F1-8
Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
9
Item 3.  Quantitative and Qualitative Disclosures About Market Risk
13
Item 4. Controls and Procedures
13
PART II
Item 1. Legal Proceedings
13
Item 1A. Risk Factors
13
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
13
Item 3. Defaults Upon Senior Securities
13
Item 4. Removed and Reserved
13
Item 5. Other Information
13
Item 6. Exhibits
13
-2-

ITEM 1.
FINANCIAL STATEMENTS.

Medical Care Technologies Inc.
(A Development Stage Company)
September 30, 2010
Index
Consolidated Balance Sheets (unaudited)
F-1
Consolidated Statements of Expenses (unaudited)
F-2
Consolidated Statement of Stockholders’ Equity (Deficit) (unaudited)
F-3
Consolidated Statements of Cash Flows (unaudited)
F-4
Notes to the Consolidated Financial Statements (unaudited)
F-5


Medical Care Technologies Inc.
(A Development Stage Company)
Consolidated Balance Sheets
(unaudited)

September 30,
December 31,
2010
2009
ASSETS
Current Assets
Cash and cash equivalents
$ 1,185 $ 475
Prepaid expenses
26,000 –
Total Current Assets
27,185 475
Property and equipment, net of accumulated depreciation of $30,000
20,000 –
Intangible assets, net of accumulated amortization of $315,846
105,282 –
Total Assets
$ 152,467 $ 475
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable
$ 68,769 $ 31,202
Advances from related parties 3,551 25,439
Due to related parties
45,000 –
Accrued liabilities
4,844 –
Loans payable
80,912 14,000
Total Current Liabilities
203,076 70,641
Loans payable
– 56,740
Total Liabilities
203,076 127,381
Commitments and Contingency (Note 6)
Subsequent Event (Note 7)
Stockholders’ Deficit
Preferred Stock, 100,000,000 shares authorized, $0.00001 par value,
No shares issued and outstanding as of September 30, 2010 and December 31, 2009
$ – $ –
Common Stock, 500,000,000 shares authorized, $0.00001 par value, 151,226,087 and
98,900,000 shares issued and outstanding as of September 30, 2010 and December 31, 2009, respectively
1,512 989
Additional Paid-in Capital
1,831,866 50,511
Deficit Accumulated During the Development Stage
(1,883,987 ) (178,406 )
Total Stockholders’ Deficit
(50,609 ) (126,906 )
Total Liabilities and Stockholders’ Deficit
$ 152,467 $ 475
(The accompanying notes are an integral part of these unaudited consolidated financial statements)
F-1

Medical Care Technologies Inc.
(A Development Stage Company)
Consolidated Statements of Expenses
(unaudited)

Period from
For the three months ended
September 30,
For the nine months ended
September 30,
February 27, 2007
(Inception)
To September 30,
2010
2009
2010
2009
2010
Expenses
General and administrative
$ 404,884 $ 13,330 $ 478,573 $ 44,332 $ 553,214
Depreciation and amortization expense
115,282 – 345,846 – 345,846
Management fees
851,000 4,700 881,000 13,700 896,692
Total Expenses
(1,371,166 ) (18,030 ) (1,705,419 ) (58,032 ) (1,795,752 )
Foreign currency exchange gain (loss)
(287 ) (729 ) (162 ) (657 ) (925 )
Loss From Continuing Operations
(1,371,453 ) (18,759 ) (1,705,581 ) (58,689 ) (1,796,677 )
Loss from Discontinued Operations:
Discontinued operations
– – – – (87,310 )
Net Loss
$ (1,371,453 ) $ (18,759 ) $ (1,705,581 ) $ (58,689 ) $ (1,883,987 )
Net Loss Per Common Share – Basic and Diluted:
Discontinued Operations
N/A N/A N/A N/A
Continuing Operations
$ (0.01 ) $ (0.00 ) $ (0.02 ) $ (0.00 )
Net Loss
$ (0.01 ) $ (0.00 ) $ (0.02 ) $ (0.00 )
Weighted Average Common Shares Outstanding–
Basic and Diluted
111,988,000 73,193,000 103,977,000 77,343,000

(The accompanying notes are an integral part of these unaudited consolidated financial statements)
F-2

Medical Care Technologies Inc.
(A Development Stage Company)
Consolidated Statement of Stockholders’ Equity (Deficit)

Deficit
Accumulated
Common Stock
Additional
During
Par
Paid-in
Development
Shares
Value
Capital
Stage
Total
Balance – February 27, 2007 (Inception)
– $ – $ – $ – $ –
Issuance of common stock for cash at $0.00001 per share
to the President of the Company
57,500,000 575 4,425 – 5,000
Issuance of common stock for cash at $0.0001 per share
41,400,000 414 35,586 – 36,000
Donated services
– – 5,000 – 5,000
Net loss for the period
– – – (37,543 ) (37,543 )
Balance – December 31, 2007
98,900,000 989 45,011 (37,543 ) 8,457
Donated services
– – 5,500 – 5,500
Net loss for the year
– – – (55,742 ) (55,742 )
Balance – December 31, 2008
98,900,000 $ 989 $ 50,511 $ (93,285 ) $ (41,785 )
Cancellation of common stock – President of Company
(57,500,000 ) (575 ) (14,425 ) – (15,000 )
Reissuance of common stock – President of the Company
57,500,000 575 14,425 – 15,000
Net loss for the year
– – – (85,121 ) (85,121 )
Balance – December 31, 2009
98,900,000 $ 989 $ 50,511 $ (178,406 ) $ (126,906 )
Cancellation of common stock for acquisition of assets
(57,300,000 ) (573 ) 573 – –
Issuance of common stock for acquisition of assets
57,300,000 573 470,555 – 471,128
Issuance of common stock for cash at $0.20 per share
500,000 5 99,995 – 100,000
Issuance of common stock for consulting services
8,250,000 83 246,917 – 247,000
Issuance of common stock for management services
38,000,000 380 835,620 – 836,000
Issuance of common stock for director fees
500,000 5 10,995 – 11,000
Issuance of common stock for business promotion services
3,826,087 38 87,962 – 88,000
Issuance of common stock for advisory services
1,250,000 12 28,738 – 28,750
Net loss for the period
– – – (1,705,581 ) (1,705,581 )
Balance – September 30, 2010
151,226,087 $ 1,512 $ 1,831,866 $ (1,883,987 ) $ (50,609 )
(The accompanying notes are an integral part of these unaudited consolidated financial statements)
F-3
Medical Care Technologies Inc.
(A Development Stage Company)
Consolidated Statements of Cash Flows
(unaudited)

Period from
Nine months ended
September 30,
February 27, 2007
(Date of Inception)
To September 30,
2010
2009
2010
Operating Activities
Net loss for the period
$ (1,705,581 ) $ (58,689 ) $ (1,883,987 )
Donated services and expenses
– – 10,500
Depreciation and amortization
345,846 – 345,846
Stock-based compensation
1,210,750 – 1,210,750
Changes in operating assets and liabilities:
Prepaid expenses
(26,000 ) (2,000 ) (26,000 )
Accounts payable
12,128 52,329 43,330
Accounts payable due to related parties 48,551 – 48,551
Accrued liabilities
4,844 (3,350 ) 4,844
Net Cash Used in Operating Activities
(109,462 ) (11,710 ) (246,166 )
Financing Activities
Proceeds from sale of common stock for cash
100,000 – 141,000
Proceeds from loans payable
10,172 – 80,912
Proceeds from advances from related party
– 1,994 25,439
Net Cash Provided by Financing Activities
110,172 1,994 247,351
Increase (Decrease) in Cash and Cash Equivalent
710 (9,716 ) 1,185
Cash – Beginning of Period
475 9,791 –
Cash – End of Period
$ 1,185 $ 75 $ 1,185
Supplemental Disclosures
Interest paid
– – –
Income taxes paid
– – –
Non-Cash Disclosures
Reclass of related party debt to/from accounts payable
$ 25,439 $ 23,445 $ 48,249
Repurchase of common stock
$ – $ – $ 15,000
Shares issued for acquisition of assets
$ 471,128 $ – $ 471,128

(The accompanying notes are an integral part of these unaudited consolidated financial statements)
F-4
Medical Care Technologies Inc.
(A Development Stage Company)
Notes to the Unaudited Consolidated Financial Statements

1.
Development Stage Company and Going Concern
Medical Care Technologies Inc. (the “Company”) was incorporated in Nevada on February 27, 2007 under the name of “Aventerra Explorations Inc” and changed its name to “AM Oil Resources & Technology Inc.” on December 3, 2008. On September 28, 2009, the Company incorporated Medical Care Technologies Inc. for the sole purpose of effecting a name change. On October 6, 2009, the Company merged with its wholly owned subsidiary and assumed the subsidiary’s name. In conjunction with the name change, the Company has also been granted a new trading symbol of MDCE.  The Company is in the development stage as defined by Financial Accounting Standards Board Accounting Standards Codification  915, “ Development Stage Entities ”.
During the nine months ended September 30, 2010, the Company issued 57.3 million common shares to acquire certain software and computer equipment associated with the development and maintenance of secure information systems which increase access to medical resources services, education and wellness, pharmaceutical and nutraceutical products. The shares represented 57.6% of the total issued and outstanding shares, resulting in a change in control. This change of control will limit the utilization of our NOL carryforwards in future tax periods. The Company’s principal business now is to open and operate private children’s health clinics throughout China.
Going Concern
These consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has not generated revenues since inception and has never paid any dividends and is unlikely to pay dividends or generate earnings in the immediate or foreseeable future. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability of the Company to obtain necessary equity financing to continue operations and to determine the existence, discovery and successful exploitation of economically recoverable reserves in its resource properties, confirmation of the Company’s interests in the underlying properties, and the attainment of profitable operations. As at September 30, 2010, the Company has a working capital deficit of $175,891 and has accumulated losses of $1,883,987 since inception. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.
Consolidation
These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in US dollars. These consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Aventerra Explorations Ltd, a company incorporated in England. All inter-company accounts and transactions have been eliminated.
Reclassification
Certain prior year amounts have been reclassified to conform with the current year presentation.
Recently Adopted Accounting Pronouncements
The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.
2.
Asset Acquisition Agreement
On January 9, 2010, the Company entered into an Asset Acquisition Agreement to acquire various computers, software, and technologies (the “assets”) held by Great Union Corporation (“Great Union”), a Hong Kong corporation. In consideration, the Company agreed to issue 57,300,000 shares of its common stock, which represents a controlling interest in Medical Care Technologies, Inc. As a result of this transaction, there was a change of control.
Based on the change in ownership, the assets were recorded based on historical basis and totaled $471,128. Pursuant to the agreement, on February 1, 2010, the Company cancelled 57,300,000 shares of common stock from the former President of the Company and issued these shares to Great Union.
F-5
2.
Asset Acquisition Agreement (continued)
The assets acquired are stated at cost and has the following remaining useful lives.  Amortization is calculated using straight-line method over the remaining lives.

Computer hardware
1 year
Equipment
2 year
Computer software and database
1 year
Amortization and depreciation expense totaled $345,846 and $nil for the nine months ended September 30, 2010 and 2009, respectively.
3.
Related Party Transactions
a)
During the nine months ended September 30, 2010, the Company recognized $45,000 of management fees. At September 30, 2010, the Company is indebted to the President of the Company for $48,551, representing $45,000 of management fees owed and $3,551 of expenditures paid on behalf of the Company.  This amount is unsecured, bears no interest and is due on demand.
b)
On September 1, 2010, the Company issued 500,000 shares of common stock to two directors of the Company at a fair value of $11,500.  Refer to Notes 5(h), 6(c) and 6(d).
c)
On September 2, 2010, the Company issued 1,000,000 shares of common stock to a director of the Company at a fair value of $23,000 for 1 year of service as a director of the Company commencing September 2, 2010.   Refer to Note 5(j).
d)
On September 13, 2010, the Company issued 38,000,000 shares of common stock to the President of the Company at a fair value of $836,000 for management services.  Refer to Note 5(l).

4.
Loans payable
a)
On August 8, 2009, the Company received $5,831 (Cdn$6,000) and entered into a promissory note agreement. Under the terms of the note, the principal of the loan is unsecured and bears no interest if repaid by April 1, 2010. The Company failed to make the principal repayment on April 1, 2010. The note currently bears interest of 12% per annum and is payable in annual installments commencing April 1, 2011. In the event of default, the principal and all accrued interest shall be due and payable thereon.
b)
On August 9, 2009, the Company borrowed $22,000 and entered into a promissory note agreement. Under the terms of the note, the principal of the loan is unsecured and bears no interest if repaid by April 1, 2010. The Company failed to make the principal repayment on April 1, 2010. The note currently bears interest of 12% per annum and is payable in annual installments commencing April 1, 2011. In the event of default, the principal and all accrued interest shall be due and payable thereon.
c)
On August 9, 2009, the Company borrowed $28,740 and entered into a promissory note. Under the terms of the note, the principal of the loan is unsecured and bears no interest if repaid by April 1, 2010. The Company failed to make the principal repayment on April 1, 2010. The note currently bears interest of 12% per annum and is payable in annual installments commencing April 1, 2011. In the event of default, the principal and all accrued interest shall be due and payable thereon.
d)
On November 18, 2009, the Company borrowed $14,000 pursuant to a promissory note. Under the terms of the note, the principal of the loan is unsecured and bears no interest if repaid by April 1, 2010. The Company failed to make the principal repayment on April 1, 2010. The note currently bears interest of 12% per annum and is payable in annual installments commencing April 1, 2011. In the event of default, the principal and all accrued interest shall be due and payable thereon.
e)
On March 30, 2010 the Company borrowed $10,341 pursuant to a promissory note. Under the terms of the note, the principal of the loan is unsecured and bears no interest if repaid by April 1, 2010. The Company failed to make the principal repayment on April 1, 2010. The note currently bears interest of 12% per annum and is payable in annual installments commencing April 1, 2011. In the event of default, the principal and all accrued interest shall be due and payable thereon.
F-6

5.
Common and Preferred Stock
a)
The preferred stock may be divided into and issued in series by the Board of Directors. The Board is authorized to fix and determine the designations, rights, qualifications, preferences, limitations and terms, within legal limitations. As of September 30, 2010 and December 31, 2009, there was no preferred stock issued and outstanding.
b)
On January 15, 2010, the Company accepted subscriptions for 500,000 units at $0.20 per unit for cash proceeds of $100,000. Each unit consists of one share of common stock of the Company and one common share purchase warrant exercisable at $0.15 per share for a period of 36 months. The Company issued the shares on February 1, 2010.
c)
On February 1, 2010, 57,300,000 shares of common stock were cancelled and returned to treasury by the former President of the Company for $nil consideration.
d)
On February 1, 2010, 57,300,000 shares of common stock with a fair value of $471,128 were issued pursuant to the Asset Acquisition Agreement with Great Union Corporation described in Note 2.
e)
On May 18, 2010, the Company issued 2,500,000 shares of common stock at a fair value of $102,500 pursuant to a consulting agreement dated May 18, 2010.  The term of the agreement is six months.
f)
On August 28, 2010, the Company issued 2,500,000 shares of common stock at a fair value of $70,000 pursuant to the consulting agreement described in Note 6(a).
g)
On August 31, 2010, the Company issued 250,000 shares of common stock at a fair value of $5,500 pursuant to a consulting agreement described in Note 6(b).
h)
On September 1, 2010, the Company issued 3,000,000 shares of common stock at a fair value of $69,000 pursuant to three consulting agreements described in Notes 6(c), (d) and (e).
i)
On September 1, 2010, the Company issued 250,000 shares of common stock at a fair value of $5,750 pursuant to the advisory board agreement described in Note 6(f).
j)
On September 2, 2010, the Company issued 1,000,000 shares of common stock at a fair value of $23,000 to a director of the Company.  Refer to Note 3(c).
k)
On September 5, 2010, the Company issued 500,000 shares of common stock at a fair value of $11,000 pursuant to the advisory board agreement described in Note 6(g).
l)
On September 13, 2010, the Company issued 38,000,000 shares of common stock to the President of the Company at a fair value of $836,000 for management services.  Refer to Note 3(d).
m)
On September 15, 2010, The Company issued 3,826,087 shares of common stock at a fair value of $88,000 pursuant to the agreement described in Note 6(h).
n)
On September 17, 2010, the Company increased its authorized shares capital of common stock to 500,000,000 shares with par value of $0.00001.
o)
During this quarter 500,000 stock options were awarded pending the approval of the Company’s stock option plan. As of September 30, 2010 and the date these financials were filed, the plan has not yet been approved.
6.
Commitments
a)
On August 28, 2010, the Company entered into an agreement for business advisory and consulting services pursuant to which the Company agreed to issue 500,000 restricted shares of common stock of the Company as consideration for entering in the agreement and 2,000,000 shares for consulting services.  The Company will also issue 250,000 stock options upon the implementation of an incentive stock option plan by the Company.  In the event that a financing transaction is arranged using a source first introduced to the Company by the consultant, the Company will pay an advisory fee at closing equal to 7% of the gross proceeds received by the Company.  The term of the agreement is 18 months.  On August 28, 2010, the Company issued 2,500,000 shares at a fair value of $70,000.  At September 30, 2010, the Company has not adopted a stock option plan and therefore has not granted the stock option to the consultant.
F-7
6.
Commitments (continued)
b)
On August 31, 2010, the Company entered into a consulting agreement for information technology consulting services.  Pursuant to the agreement, the Company agreed to i) issue 250,000 shares of common stock; ii) grant a stock option which entitles the holder to purchase 50,000 shares of Company’s common stock upon the implementation of an incentive stock option plan by the Company.  The term of the agreement is twelve months.  On August 31, 2010, the Company issued 250,000 shares at a fair value of $5,500.  At September 30, 2010, the Company has not adopted a stock option plan and therefore has not granted the stock option to the consultant.
c)
On September 1, 2010, the Company entered into a consulting agreement for public relations and marketing services.  Pursuant to the agreement, the Company agreed to issue 250,000 shares of common stock and a stock option which entitles the holder to purchase 50,000 shares of common stock. The agreement may be terminated at any time by either party. On September 1, 2010, the Company issued 250,000 shares of common stock at a fair value of $5,750.  At September 30, 2010, the Company has not adopted a stock option plan and therefore has not granted the stock option to the consultant.
d)
On September 1, 2010, the Company entered into a consulting agreement for information technology consulting services.  Pursuant to the agreement, the Company agreed to issue 250,000 shares of common stock and a stock option which entitles the holder to purchase 50,000 shares of common stock.  The agreement may be terminated at any time by either party. On September 1, 2010, the Company issued 250,000 shares of common stock at a fair value of $5,750.  At September 30, 2010, the Company has not adopted a stock option plan and therefore has not granted the stock option to the consultant.
e)
On September 1, 2010, the Company entered into a consulting agreement related to strategic, planning, reporting and other general business consultation for its operations in the United States and China.  Pursuant to the agreement, the Company agreed to issue 2,500,000 restricted shares of common stock of the Company.  In addition, if the consultant is materially involved in a completed merger and acquisition (the “Transaction”) with a company introduced by the Company, the Company agrees to pay the consultant 5% of the total value of the Transaction in the same ratio of cash and/or stock as the Transaction.  If the consulting is materially involved in a completed Transaction with a company introduced by the consultant, the Company agrees to pay the consultant 10% of the total value of the Transaction in the same ratio of cash and/or stock as the Transaction.  The term of the agreement is 1 year and may be renewed for an additional one year.  On September 1, 2010, the Company issued 2,500,000 shares at a fair value of $57,500 to the consultant.
f)
On September 1, 2010, the Company entered into an advisory board agreement pursuant to which the Company agreed to issue 250,000 restricted shares of common stock of the Company and a stock option to purchase 50,000 shares.  The advisor will devote up to 8 days in each twelve month period.  The agreement may be terminated at any time by either party. On September 1, 2010, the Company issued 250,000 shares of common stock at a fair value of $5,750.  At September 30, 2010, the Company has not adopted a stock option plan and therefore has not granted the stock option to the advisor.
g)
On September 5, 2010, the Company entered into an advisory board agreement pursuant to which the Company agreed to issue 500,000 restricted shares of common stock of the Company and a stock option to purchase 50,000 shares.  The advisor will devote up to 8 days in each twelve month period.  The agreement may be terminated at any time by either party. On September 5, 2010, the Company issued 500,000 shares of common stock at a fair value of $11,000.  At September 30, 2010, the Company has not adopted a stock option plan and therefore has not granted the stock option to the advisor.
h)
On September 15, 2010, the Company entered into an agreement with Accredited Members, Inc. (“AMI”), pursuant to which the Company will create and post a corporate profile on AMI’s community website which provides AMI’s members a channel to present information regarding their business to other members.  Under the terms of the agreement, the Company agreed to pay $1,000 per month and issue $88,000 worth of restricted shares of common stock of the Company within 20 days of the signing of the agreement.  If at the end of the 180-day restricted stock period (covered under Rule 144), the shares of common stock of the Company are valued at less than $88,000 (based on the lesser of the closing bid price at the 180 day mark or the trailing 20 day closing bid average), the Company will issue additional shares to equal the original $88,000 stock value at the start of the agreement.  On September 15, 2010, the Company issued 3,826,087 shares of common stock at a fair value of $88,000.
7.
Subsequent Event
On October 22, 2010, the Company signed a proposed term sheet for a $50,000 convertible debenture.  According to the term sheet, the convertible debenture is due 9 months after issuance, bears interest at 8% per annum and is convertible at 39.9% discount of the average of the lowest 3 trading prices during the 10 trading day period ended on trading day prior to the date of the conversion.  The debenture holder will be limited to convert no more than 4.99% of the issued and outstanding common stock of the Company at time of conversion at any one time.
F-8

ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Forward-Looking Statements
This quarterly report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.
We are a start-up, development stage-corporation and have not yet generated or realized any revenues from our business activities. We incurred a loss of $1,371,453 for the quarter ended September 30, 2010 and had an accumulated deficit of $1,883,987 since inception.  The Company’s ability to continue as a going concern is uncertain.  While management of the Company believes that the Company will be successful in its current and planned operating activities, there can be no assurance that the Company will be successful in the achievement of opening and operating private pediatric clinics, sale and implementation of its medical software programs, or sales of its products that will generate sufficient revenues to earn a profit and sustain the operations of the Company.  The Company also intends to conduct additional capital formation activities through the issuance of its common stock and loans.

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern.  The Company has not established sufficient sources of revenues to cover its operating costs and expenses.  As such, it has incurred an operating loss since inception.  Further, as of September 30, 2010 the cash resources of the Company were insufficient to meet its planned business objectives.  These and other factors raise substantial doubt about the Company’s ability to continue as a going concern.  The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

We are actively pursuing short term and long term financing solutions.

Our Business

On January 9, 2010, we signed an Asset Acquisition Agreement (“Asset Agreement”) with Great Union Corporation (“Great Union”). In consideration of the issuance of 57,300,000 shares of our common stock, we acquired Great Union’s technologies associated with the development and maintenance of secure information systems which increase access to medical resources services, education and wellness, pharmaceutical and nutraceutical products.

Our mission now is to open and operate private children’s health clinics throughout China. Concurrent with, and in addition to the clinics we operate, it is our plan to add to our bottom revenue line by offering affordable, standardized and secure software information systems to electronically connect healthcare providers, academic institutions, pharmaceutical and nutraceutical companies, alternative health companies and individual consumers with healthcare information, products and services in China.   Initially, we aim to generate e-management revenues and nutraceutical and pharmaceutical product distribution revenues.

We are a Chinese medical technology company engaged principally in the business of i) opening and operating private healthcare services to children in China;  ii) developing and maintaining online secure medical information systems used by hospitals and other healthcare institutions and; iii) selling pharmaceutical, nutraceutical and herbal products online and in our proposed private healthcare clinics.
Our current operations consist of three business segments: Children’s Medical Clinics, Medical Management Software Systems, and Pharmaceutical and Nutraceutical Products.

9


Private Pediatric Clinics

The company plans to seize the opportunities available for businesses that provide medical type services in China by opening and operating private pediatric clinics and mainly locating them in economically developing and/ developed provinces and urban areas. Subsequent to the quarter ended September 30, 2010, we have entered into verbal discussions with Chinese health officials to initiate our pediatric health care objectives.

Medical Management Software Systems

Modern technology has made it possible to gather and present health care information economically and efficiently and we have positioned ourselves to lead the effort to marry technology and health care information dissemination through two software information systems we have developed. Our technology will allow the user to register, monitor, test, interact and manage health records in a seamless fashion. Our software delivery information systems platforms are - Med-Suite™ Professional Practice Management and Tele-Health™ Suite. The primary customers served by our software systems are hospitals and clinics; physicians’ office practices; pharmaceutical companies and; other healthcare providers. We also plan to install the software systems in our pediatric clinics.

Pharmaceutical and Nutraceutical Products

It is our strategy to develop or source and sell high-quality pharmaceutical and nutraceutical products and a wide variety of other merchandise, including over-the-counter medicines, herbal products, personal care products, family care products in our planned pediatric clinics, through our online store website, retail pharmacies and through established sales and distribution channels in China. We will also offer private label products, which we believe will distinguish us from our key competitors. Further, our target customers in this segment are retail pharmacies, pharmaceutical companies; hospitals; physicians’ office practices and; the general public.

Limited Operating History and Need for Additional Capital

There is no historical financial information about us upon which to base an evaluation of our performance. We have just begun our development operations and have not yet generated revenues from our activities. In January 2010, we signed the Asset Acquisition Agreement with Great Union and appointed new Board members to carry forth the Company’s operations according to its business plan. Opening and operating private children’s health clinics, e-management online healthcare services, and selling and distribution of our pharmaceutical and nutraceutical products are all potential revenue streams currently being developed by us. Although we expect to generate revenues from our business activities, there is no guarantee we will be successful. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible delays in obtaining licenses to operate health services in China.  Because we have no operating history we cannot reliably forecast our future operations.

We have utilized funds obtained from our January 13, 2010 private placement for corporate organizational purposes, license payments and; software developmental costs.

In the short term, we require additional funding for legal and professional fees, continued software development costs, license fees, market feasibility research studies, accounts payables and general operating expenses. Subsequent to our quarter ended September 30, 2010, we signed a proposed term sheet for a $50,000 convertible debenture.  According to the term sheet, the convertible debenture is due 9 months after issuance, bears interest at 8% per annum and is convertible at 39.9% discount of the average of the lowest 3 trading prices during the 10 trading day period ended on trading day prior to the date of the conversion.  The debenture holder will be limited to convert no more than 4.99% of the issued and outstanding common stock of the Company at time of conversion at any one time.

In the long term, our anticipated revenue streams over the next three years are expected to come from operating children’s clinics, our e-management online healthcare market, pharmaceutical and nutraceutical supply market. We plan to develop in each of our business segments new products and services that provide increased benefits to customers. Our ability to obtain long-term growth will depend on a number of factors, including our ability to expand our business (including geographical expansion), source new products with higher gross profit margins, and obtain operating efficiency and organizational effectiveness.

10


To become profitable and competitive, we must be successful in obtaining license approvals from Chinese government health authorities in order to be able to open and operate private pediatric clinics throughout China and to generate substantial revenues and profits. Subsequent to the quarter ended September 30, 2010, the Company’s Chief Executive Officer has entered into various discussions with appropriate health authorities to enable us to move forward with our pediatric health care initiatives. We have also entered into discussions with Chinese investment banks that may provide long term strategic financing for us.

We have no assurance that financing will be available to us on satisfactory terms. If financing is not available on satisfactory terms, we may be unable to continue, develop or expand our activities. Equity financing could result in additional dilution to existing shareholders.

Results of Operations
Net Loss. We incurred a net loss of $1,371,453 for the quarter ended September 30, 2010, compared to a net loss of $18,759 for the quarter ended September 30, 2009. This was mainly as a result of: i) an increase of $846,300 in management fees ($851,000 in 2010 and $4,700 in 2009) due to an issuance of 38,000,000 shares of common stock to the President of the Company at a fair value of $836,000 for management services. The 38,000,000 share issuance is subject to a Two Year Lock Up Agreement; ii) an increase of $391,554 in general and administrative expenses ($404,884 in 2010 and $13,330 in 2009) due to an increase of stock based compensation with a fair value of $374,750 pursuant to various information technology, business advisory, public relations and general consulting services and director remuneration and advisory board compensation;  iii) an increase of $115,282 in depreciation and amortization expense in the quarter ended September 30, 2010 on the medical technology acquired in the Asset Acquisition Agreement with Great Union Corporation.

We incurred a net loss of $1,705,581 for the nine months ended September 30, 2010, compared to a net loss of $58,689 for the nine months ended September 30, 2009. This was mainly due to an increase of: i) $867,300 in management fees ($881,000 in 2010 and $13,700 in 2009) due to an issuance of 38,000,000 shares of common stock to the President of the Company at a fair value of $836,000 for management services. The 38,000,000 share issuance is subject to a Two Year Lock Up Agreement; ii) $434,241 in general and administrative expenses ($478,573 in 2010 and $44,332 in 2009) due to an increase of stock based compensation with a fair value of $374,750 pursuant to various information technology, business advisory, public relations and general consulting services and director remuneration and advisory board compensation and an increase in legal and accounting costs pursuant to the Asset Acquisition Agreement; iii) $345,846 in depreciation and amortization expense in the nine months ended September 30, 2010 on the medical technology acquired in the Asset Acquisition Agreement with Great Union Corporation.
From February 27, 2007 (inception date) to September 30, 2010 we incurred a net loss of $1,883,987 and had a working capital deficiency of $175,891.

Our ability to achieve profitable operations depends on developing revenue through the operation of private pediatric clinics throughout China. Our expectations are that we will not begin to show profitable results from the operation of pediatric clinics until Year 2.

Liquidity and Capital Resources

As of September 30, 2010, our total assets were $152,467 and our total liabilities were $203,076.  Total assets increased from December 31, 2009 by $151,992 due to an increase in prepaid expenses of $26,000 ($26,000 in 2010 and $-0- in 2009); property and equipment of $20,000 ($20,000 in 2010 and $-0- in 2009) and; an increase in intangible assets of $105,282 ($105,282 in 2010 and $-0- in 2009). Total liabilities increased by $75,695.  This is mainly due to an increase in accounts payable and accrued liabilities of $42,411 ($73,613 in 2010 and $31,202 in 2009); an increase in loans payable of $10,172 ($80,912 in 2010 and $70,740 in 2009) and; an increase in due to related parties of $23,112 ($48,551 in 2010 and $25,439 in 2009).
The accompanying financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. We have not generated any revenues and we do not anticipate to generate any revenues until i) we begin implementing our medical management software systems and devices in hospitals and clinics; ii) sourcing, marketing and selling pharmaceutical and nutraceutical products to healthcare providers and the general public and; iii) opening and serving patients in our pediatric clinics.  Accordingly, we must raise cash from private investors, through equity financings or by developing strategic alliances with other leading, world class players in the health industry. We are actively pursuing financing options to carry out our business operations.  We have used the monies raised in our January 13, 2010 private placement for license fees and corporate purposes. Our success or failure will be determined by creating alliances with healthcare providers who need our medical technology, selling a large volume or our products and opening a number of private pediatric clinics throughout China.

11
On January 13, 2010, we completed a non-brokered private placement of 500,000 units at a price of US$0.20 per unit for total proceeds of US$100,000.  Each unit purchased is comprised of one share of common stock and one Series A Warrant. Each Series A Warrant is non-transferable and is convertible into one share of common stock upon payment of $0.15 per Series A Warrant, exercisable for a period of twenty four (24) months.  The units were sold pursuant to the exemption from registration contained in Regulation S of the Securities Act of 1933 in that the transaction took place outside the United States of America and the purchaser was a non-US person as defined in Regulation S. The securities that comprise the units are ‘restricted securities’ as that term is defined in Rule 144 of the Securities Act of 1933.

Cash on hand as of November 19, 2010 is $1,185. Net cash used for operating activities was $158,013 for the quarter ended September 30, 2010 compared to operating activities of $11,710 for the quarter ended September 30, 2009.  Operating expenses for the quarter ended September 30, 2010 included i) $345,846 in depreciation and amortization expenses; ii) stock based compensation of $1,210,750 of which an issuance of 38,000,000 common stock at a fair value of $836,000 was paid to the President of the Company for management services; 8,250,000 common stock at a fair value of $247,000 was paid to consultants for various information technology, business advisory, public relations and general consulting services; 3,826,087 common stock at a fair value of $88,000 was paid to a firm in exchange for the Company posting its corporate profile on the firm’s community website; 1,000,000 common stock at a fair value of $23,000 was paid to a former director as remuneration and; 750,000 common stock at a fair value of $16,750 was paid to 2 advisors pursuant to advisory board agreements; iii) paid down prepaid expenses of $26,000 and; iv) decrease of $16,972 in accounts payable and accrued liabilities. We anticipate that overhead costs will increase in the near term as we increase our operational activities.

Cash flows provided by financing activities accounted for $158,723 for the quarter ended September 30, 2010 compared to financing activities of $1,994 for the quarter ended September 30, 2009.  For the quarter ended September 30, 2010, financing activities included an issuance of common stock for cash of $100,000; an increase in loans payable of $10,172 and; increase in related party loans of $48,551.

Limited Capital

We are currently in discussions with investors to raise the funds necessary to carry out our operational plans and continue our business activities. Subsequent to our quarter ended September 30, 2010, we signed a proposed term sheet for a $50,000 convertible debenture.  According to the term sheet, the convertible debenture is due 9 months after issuance, bears interest at 8% per annum and is convertible at 39.9% discount of the average of the lowest 3 trading prices during the 10 trading day period ended on trading day prior to the date of the conversion.  The debenture holder will be limited to convert no more than 4.99% of the issued and outstanding common stock of the Company at time of conversion at any one time.

Other than as described above, we have no commitments for any additional financing, and there can be no assurance that, if needed, additional capital will be available to use on commercially acceptable terms or at all. Our failure to raise capital as needed would significantly restrict our growth and hinder our ability to compete. We may need to curtail expenses, and forgo business opportunities. Additional equity financings are likely to be dilutive to holders of our common stock and debt financing, if available, may involve significant payment obligations and covenants that restrict how we operate our business. If we are unable to secure funds to finance our operations, we may examine other possibilities, including, but not limited to, mergers or acquisitions.

Management believes the ability of the Company to continue as a going concern, earn revenues and achieve profitability is highly dependent on a number of factors including our ability to obtain sufficient financing to prepare a market analysis for submission to the appropriate state authorities in China in order to procure the necessary licensing approvals of establishing children’s health clinics.  We have already completed a White Paper which outlines our vision for operating children’s health clinics in China.
The Company has not generated revenues since inception and has never paid any dividends and is unlikely to pay dividends or generate earnings in the immediate or foreseeable future. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability of the Company to obtain necessary equity financing to continue operations and to determine the existence, discovery and successful exploitation of economically recoverable reserves in its resource properties, confirmation of the Company’s interests in the underlying properties, and the attainment of profitable operations. As at September 30, 2010, the Company has a working capital deficit and has accumulated losses of since inception. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.

Off-Balance Sheet Arrangements

We have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

12

ITEM 3.                      QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.
ITEM 4.                      CONTROLS AND PROCEDURES.

Under the supervision and with the participation of our management, including the Principal Executive Officer and Principal Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based on that evaluation, the Principal Executive Officer and Principal Financial Officer have concluded that these disclosure controls and procedures are not effective. In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework . Based on our assessment, we believe that, as of September 30, 2010, our internal control over financial reporting was not effective based on those criteria due to a lack of segregation of duties, a lack of qualified accounting staff and an overreliance on consultants in our accounting and financial reporting process. A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Notwithstanding, at this time management has decided that considering the abilities of the persons involved and the control procedures now in place, the risks associated with such lack of segregation are low and the potential benefits of adding employees to further segregate duties do not justify the substantial expenses associated with such increases. Management will periodically reevaluate this situation.
There were no changes in our internal control over financial reporting during the quarter ended September 30, 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1.                      LEGAL PROCEEDINGS.
We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.
ITEM 1A.                   RISK FACTORS.
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.
ITEM 2.                      UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
None.
ITEM 3.                      DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4.                      [REMOVED AND RESERVED].
ITEM 5.                      OTHER EVENTS.
None.
ITEM 6.                      EXHIBITS.
The following documents are included herein:

Exhibit No.
Document Description
10.6
Accredited Members Inc. Annual Profile Agreement dated September 15, 2010.
31.1
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
Certification of Chief Executive Officer and Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
13

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDICAL CARE TECHNOLOGIES INC.
Dated:  November 19, 2010
BY:
/s/ Ning C. Wu
Ning C. Wu,
President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer and a member of the Board of Directors.

14

EXHIBIT INDEX

Exhibit No.
Document Description
10.6
Accredited Members Inc. Annual Profile Agreement dated September 15, 2010.
31.1
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
Certification of Chief Executive Officer and Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

15
TABLE OF CONTENTS